Alliancebernstein L.P. Biogen Inc. Transaction History

Alliancebernstein L.P.

$275 Billion
Q1 2024

A detailed history of Alliancebernstein L.P. transactions in Biogen Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 201,891 shares of BIIB stock, worth $46.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

201,891

Previous 229,813 12.15%

Holding current value

$46.2 Million

Previous $59.5 Million 26.8%

% of portfolio

0.02%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$212.02 - $267.71 $5.92 Million - $7.47 Million	-27,922 Reduced 12.15%	201,891 $43.5 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $4.83 Million - $5.81 Million	-21,691 Reduced 8.62%	229,813 $59.5 Million
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $2.81 Million - $3.17 Million	11,105 Added 4.62%	251,504 $64.6 Million
Q2 2023 Aug 15, 2023	SELL	$275.25 - $318.06 $14.6 Million - $16.9 Million	-53,124 Reduced 18.1%	240,399 $68.5 Million
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $13 Million - $14.8 Million	50,545 Added 20.8%	293,523 $81.6 Million

Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $2.68 Million - $3.25 Million	10,599 Added 4.56%	242,978 $67.3 Million
Q3 2022 Nov 15, 2022	BUY	$194.69 - $268.46 $350,636 - $483,496	1,801 Added 0.78%	232,379 $62 Million
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $6.77 Million - $8.05 Million	36,088 Added 18.56%	230,578 $47 Million
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $151,528 - $190,917	782 Added 0.4%	194,490 $41 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $9.84 Million - $12.6 Million	-43,928 Reduced 18.49%	193,708 $46.5 Million
Q3 2021 Nov 10, 2021	BUY	$282.99 - $369.05 $2.06 Million - $2.69 Million	7,277 Added 3.16%	237,636 $67.2 Million
Q2 2021 Jul 30, 2021	SELL	$259.0 - $414.71 $7 Million - $11.2 Million	-27,014 Reduced 10.5%	230,359 $79.8 Million
Q1 2021 May 06, 2021	SELL	$242.95 - $284.63 $4.76 Million - $5.58 Million	-19,602 Reduced 7.08%	257,373 $72 Million
Q4 2020 Feb 08, 2021	BUY	$236.26 - $355.63 $1.41 Million - $2.12 Million	5,955 Added 2.2%	276,975 $67.8 Million
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $2.83 Million - $3.27 Million	-10,691 Reduced 3.8%	271,020 $76.9 Million
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $9.07 Million - $12 Million	-35,082 Reduced 11.07%	281,711 $75.4 Million
Q1 2020 May 14, 2020	SELL	$268.85 - $341.04 $30.6 Million - $38.8 Million	-113,661 Reduced 26.4%	316,793 $100 Million
Q4 2019 Feb 18, 2020	SELL	$220.06 - $304.07 $234 Million - $324 Million	-1,064,632 Reduced 71.21%	430,454 $128 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $51.2 Million - $57.4 Million	-235,507 Reduced 13.61%	1,495,086 $348 Million
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $170 Million - $187 Million	-773,943 Reduced 30.9%	1,730,593 $405 Million
Q1 2019 May 14, 2019	SELL	$216.71 - $338.96 $70.8 Million - $111 Million	-326,692 Reduced 11.54%	2,504,536 $592 Million
Q4 2018 Feb 13, 2019	SELL	$278.5 - $352.75 $80.7 Million - $102 Million	-289,916 Reduced 9.29%	2,831,228 $852 Million
Q3 2018 Nov 08, 2018	SELL	$293.51 - $383.83 $208 Million - $273 Million	-710,281 Reduced 18.54%	3,121,144 $1.1 Billion
Q2 2018 Aug 13, 2018	SELL	$257.52 - $306.91 $49.8 Million - $59.3 Million	-193,345 Reduced 4.8%	3,831,425 $1.11 Billion
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $159 Million - $224 Million	610,098 Added 17.87%	4,024,770 $1.1 Billion
Q4 2017 Feb 13, 2018	BUY	$307.64 - $344.58 $224 Million - $251 Million	727,007 Added 27.05%	3,414,672 $1.09 Billion
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $756 Million - $886 Million	2,687,665	2,687,665 $842 Million

Others Institutions Holding BIIB

# of Institutions

1,047

Shares Held

126M

Call Options Held

1.37M

Put Options Held

1.35M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Biogen Inc. Transaction History